161 related articles for article (PubMed ID: 23808401)
21. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer.
Wang Y; Dong QZ; Fu L; Stoecker M; Wang E; Wang EH
Mol Carcinog; 2013 Nov; 52(11):890-9. PubMed ID: 22753141
[TBL] [Abstract][Full Text] [Related]
22. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.
Cooper WA; O'toole S; Boyer M; Horvath L; Mahar A
Pathology; 2011 Feb; 43(2):103-15. PubMed ID: 21233671
[TBL] [Abstract][Full Text] [Related]
23. Tissue sampling in lung cancer: a review in light of the MERIT experience.
Reck M; Hermes A; Tan EH; Felip E; Klughammer B; Baselga J
Lung Cancer; 2011 Oct; 74(1):1-6. PubMed ID: 21658788
[TBL] [Abstract][Full Text] [Related]
24. [Expression of MAGE-3 gene product in non-small cell lung cancer].
Liu Q; Zhang C; Feng K
Zhonghua Zhong Liu Za Zhi; 2000 Mar; 22(2):138-40. PubMed ID: 11776642
[TBL] [Abstract][Full Text] [Related]
25. A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?
Schlick K; Troch M; Placher-Sorko G; Faber V; Neureiter D; Berghoff AS; Preusser M; Greil R; Hopfinger G
Ann Hematol; 2015 Feb; 94(2):345-6. PubMed ID: 25055797
[No Abstract] [Full Text] [Related]
26. Prognostic evaluation of CapG, gelsolin, P-gp, GSTP1, and Topo-II proteins in non-small cell lung cancer.
Zhu WY; Hunag YY; Liu XG; He JY; Chen DD; Zeng F; Zhou JH; Zhang YK
Anat Rec (Hoboken); 2012 Feb; 295(2):208-14. PubMed ID: 22190510
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.
McMillen E; Ye F; Li G; Wu Y; Yin G; Liu W
Exp Lung Res; 2010 Nov; 36(9):531-7. PubMed ID: 20939760
[TBL] [Abstract][Full Text] [Related]
28. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment.
Hsu HS; Chen TP; Wen CK; Hung CH; Chen CY; Chen JT; Wang YC
J Pathol; 2007 Dec; 213(4):412-9. PubMed ID: 17973238
[TBL] [Abstract][Full Text] [Related]
29. The 2015 Physician Quality Reporting System reflects pathologists' role in lung cancer biomarker testing.
Cagle PT; Allen TC
Arch Pathol Lab Med; 2015 Apr; 139(4):445. PubMed ID: 25643045
[No Abstract] [Full Text] [Related]
30. [Tumor-associated prognostic parameters in non-small-cell bronchial carcinoma].
Thomas M
Pneumologie; 1997 Jul; 51(7):669-77. PubMed ID: 9333800
[No Abstract] [Full Text] [Related]
31. Invited commentary.
Korst RJ
Ann Thorac Surg; 2006 Jul; 82(1):248. PubMed ID: 16798223
[No Abstract] [Full Text] [Related]
32. Decrease of PDSS2 expression, a novel tumor suppressor, in non-small cell lung cancer.
Chen P; Yu J; Knecht J; Chen Q
Cancer Epidemiol; 2013 Apr; 37(2):166-71. PubMed ID: 23312889
[TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor-1 receptor protein expression and gene copy number alterations in non-small cell lung carcinomas.
Tsuta K; Mimae T; Nitta H; Yoshida A; Maeshima AM; Asamura H; Grogan TM; Furuta K; Tsuda H
Hum Pathol; 2013 Jun; 44(6):975-82. PubMed ID: 23266446
[TBL] [Abstract][Full Text] [Related]
34. Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer.
Gazdar AF; Mulshine JL; Kramer BS
Immunol Ser; 1990; 53():453-68. PubMed ID: 1966068
[No Abstract] [Full Text] [Related]
35. [Are the ATS (American Thoracic Society) and the ERS (European Respiratory Society) correct in not recommending routine tumor marker assays foeening, staging, or evaluation of non-small cell lung cancer?].
Watine J; Charet JC
Rev Mal Respir; 1999 Apr; 16(2):139-49. PubMed ID: 10339757
[TBL] [Abstract][Full Text] [Related]
36. The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC).
Grimminger PP; Schneider PM; Metzger R; Vallböhmer D; Danenberg KD; Danenberg PV; Hölscher AH; Brabender J
Lung Cancer; 2010 Oct; 70(1):82-7. PubMed ID: 20064672
[TBL] [Abstract][Full Text] [Related]
37. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.
Dacic S
Expert Rev Mol Diagn; 2007 Jan; 7(1):77-86. PubMed ID: 17187486
[TBL] [Abstract][Full Text] [Related]
38. The classification of lung carcinoma: time to change the morphology-based approach?
Pelosi G; Sonzogni A; Viale G
Int J Surg Pathol; 2010 Jun; 18(3):161-72. PubMed ID: 20460313
[TBL] [Abstract][Full Text] [Related]
39. HMGA2 overexpression in non-small cell lung cancer.
Meyer B; Loeschke S; Schultze A; Weigel T; Sandkamp M; Goldmann T; Vollmer E; Bullerdiek J
Mol Carcinog; 2007 Jul; 46(7):503-11. PubMed ID: 17477356
[TBL] [Abstract][Full Text] [Related]
40. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
